Roger Whiting
Keine laufenden Positionen mehr
Profil
Roger Whiting is President, Chief Scientific Officer and a Co-Founder of ROXRO PHARMA, Inc. He has 30 years of experience in the pharmaceutical industry.
Dr. Whiting received a Bachelor of Science degree from the University of Bradford and an MD from Aston University.
Ehemalige bekannte Positionen von Roger Whiting
| Unternehmen | Position | Ende |
|---|---|---|
ROXRO Pharma, Inc.
 ROXRO Pharma, Inc. Pharmaceuticals: MajorHealth Technology ROXRO Pharma, Inc. develops hospital strength acute pain products. Its products include ROX-888, an intranasal formulation for the treatment of dental and postoperative pain; ROX-828, a non-opioid and non-triptan intranasal product for the treatment of migraine; and SPRIX nasal spray for the short-term management of acute moderate to moderately severe pain that requires analgesia at the opioid level. The company was founded by Michael E Fitzgerald, Roger Whiting and Roberto Pedro Rosenkranz in 1999 and is headquartered in Menlo Park, CA. | Gründer | - |
Ausbildung von Roger Whiting
| University of Bradford | Undergraduate Degree |
| University of Aston | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
ROXRO Pharma, Inc.
ROXRO Pharma, Inc. Pharmaceuticals: MajorHealth Technology ROXRO Pharma, Inc. develops hospital strength acute pain products. Its products include ROX-888, an intranasal formulation for the treatment of dental and postoperative pain; ROX-828, a non-opioid and non-triptan intranasal product for the treatment of migraine; and SPRIX nasal spray for the short-term management of acute moderate to moderately severe pain that requires analgesia at the opioid level. The company was founded by Michael E Fitzgerald, Roger Whiting and Roberto Pedro Rosenkranz in 1999 and is headquartered in Menlo Park, CA. | Health Technology |
